Observational studyPloS one2025
The bilirubin-to-albumin ratio as a potential prognostic biomarker for all-cause mortality in patients with acute decompensated cirrhosis: A prospective study.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Secondary Hepatic Dysfunction in Critically Ill Children: Prognostic Associations Beyond PRISM III and PELOD-2 Scores.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute decompensation (AD) of liver cirrhosis is a life-threatening condition with high mortality and a significant healthcare burden. Although various prognostic models are available, their complexity often limits their practical utility in clinical settings. The bilirubin-to-albumin (B/A) ratio has emerged as a potential biomarker for critically ill patients. Despite its simplicity, the prognostic value of the B/A ratio in patients with AD remains uncertain.
methodsThis two-center, prospective observational study screened 748 participants. After follow-up and application of the exclusion criteria, 279 patients with AD were included in the final analysis. The B/A ratio was evaluated for its association with 30-day, 90-day, and 180-day mortality.
resultsKaplan-Meier survival analysis demonstrated worse survival outcomes in patients with higher B/A ratios, with 180-day survival rates of 95.7%, 87.1%, 64.3%, and 56.5% from the lowest to highest quartiles, respectively. ROC curve analysis further validated its prognostic value, identifying optimal B/A ratio cutoffs of 3.30, 3.17, and 3.10 for predicting 30-day, 90-day, and 180-day mortality, with corresponding AUC values of 0.77, 0.79, and 0.75, indicating moderate predictive ability. The sensitivity and specificity at these cutoff points were 81.8% and 63.0% (30-day), 81.8% and 66.0% (90-day), and 77.9% and 68.7% (180-day). Furthermore, the B/A ratio demonstrated a prognostic performance comparable to MELD, MELD-Na, MELD 3.0, Child-Pugh, ALBI, EZ-ALBI, and PALBI, with no statistically significant differences in AUC values (p > 0.05).
conclusionThe B/A ratio is a simple and effective prognostic biomarker, with a higher B/A ratio associated with increased mortality in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.